TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Vitamin A in Fortified Extruded Rice in School Children in Satun, Thailand
Brief Summary: The project aims to evaluate the potential impact triple fortified rice grains, mixed into natural rice grains, can have on vitamin A status if fed to school children in Southern Thailand. Within a 60 day intervention study, changes in vitamin A status in young children fed the fortified rice compared to children consuming non-fortified rice will be assessed.


Options:
A: Arm Label: fortified extruded rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fortified extruded rice | Intervention Type: DIETARY_SUPPLEMENT; Name: fortified extruded rice; Assigned to Arm(s): fortified extruded rice
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
C: Arm Label: Hgh micronutrients, high n-3 fatty acid treatment Arm; Type: EXPERIMENTAL; Interventions: Behavioral: micronutrients | Arm Label: low micronutrients, high n-3 fatty acid treatment; Type: EXPERIMENTAL; Interventions: Behavioral: micronutrients | Arm Label: low micronutrients, low n-3 fatty acid treatment.; Type: EXPERIMENTAL; Interventions: Behavioral: micronutrients | Arm Label: high micronutrients, low n-3 fatty acid treatment; Type: EXPERIMENTAL; Interventions: Behavioral: micronutrients | Intervention Type: BEHAVIORAL; Name: micronutrients; Assigned to Arm(s): Hgh micronutrients, high n-3 fatty acid treatment Arm, high micronutrients, low n-3 fatty acid treatment, low micronutrients, high n-3 fatty acid treatment, low micronutrients, low n-3 fatty acid treatment.
D: Arm Label: triple fortified extruded rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Triple fortified extruded tice (Fe, Zn and vitamin A) | Arm Label: regular meal; Type: OTHER; Interventions: Dietary Supplement: Triple fortified extruded tice (Fe, Zn and vitamin A) | Intervention Type: DIETARY_SUPPLEMENT; Name: Triple fortified extruded tice (Fe, Zn and vitamin A); Assigned to Arm(s): regular meal, triple fortified extruded rice

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incidence of Postoperative Cognitive Dysfunction in Elderly Patients Following Desflurane or Sevoflurane General Anesthesia: A Randomized, Controlled Trial
Brief Summary: The use of desflurane in elderly subjects (\>65 years old) undergoing general anesthesia with endotracheal intubation will result in decreased POCD compared to sevoflurane if the patient's MAP is within 20% of the patient's baseline and the cerebral suppression state index stays within the moderately anesthetized range during general anesthesia.


Options:
A: Arm Label: EEG guided protocol; Type: EXPERIMENTAL; Interventions: Device: a pragmatic EEG-guided anesthetic protocol | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: a pragmatic EEG-guided anesthetic protocol; Assigned to Arm(s): EEG guided protocol
B: Arm Label: desflurane and sevoflurane; Type: N/A; Interventions: Other: The intervention will be Mini-Mental Status Examination (MMSE) | Intervention Type: OTHER; Name: The intervention will be Mini-Mental Status Examination (MMSE); Assigned to Arm(s): desflurane and sevoflurane
C: N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3-6 Years, Attending Day Care Centers
Brief Summary: This multicentric, randomized, double-blind and controlled study aims to examine the effect of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel® = tested product) on the incidence of respiratory and gastro-intestinal common infectious diseases (cumulated number of infections during the intervention period: primary criteria) in children aged 3-6 years, attending day care centers.Volunteers received either 200g/day of tested product (N=300) or control product (N=299) for 3-months, followed by a 1-month follow-up.


Options:
A: Arm Label: fermented milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented milk | Arm Label: fermented rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented rice | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented milk; Assigned to Arm(s): fermented milk | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented rice; Assigned to Arm(s): fermented rice
B: Arm Label: 1 = Tested product; Type: ACTIVE_COMPARATOR; Interventions: Other: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®) | Arm Label: 2 = Control product; Type: SHAM_COMPARATOR; Interventions: Other: 2-Non fermented dairy product (control) | Intervention Type: OTHER; Name: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®); Assigned to Arm(s): 1 = Tested product | Intervention Type: OTHER; Name: 2-Non fermented dairy product (control); Assigned to Arm(s): 2 = Control product
C: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: low calcium milk of 180 ml | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml + probiotics | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml + probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: low calcium milk of 180 ml; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml + probiotics; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml + probiotics; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Sham Controlled Trial of Vertebroplasty for Painful Acute Osteoporotic Vertebral Fractures
Brief Summary: The standard care in patients with a painful osteoporotic vertebral compression fracture (VCF) is conservative therapy. Percutaneous vertebroplasty (PV), is a new minimally invasive technique for pain treatment in which bone cement is injected in the fractured vertebra. Recent RCTs provide conflicting results: two sham-controlled studies show no benefit of PV while an unmasked but controlled RCT found significantly better pain relief after PV at acceptable costs.


Options:
A: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): 1
B: Arm Label: Vertebroplasty; Type: EXPERIMENTAL; Interventions: Device: Percutaneous vertebroplasty | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham vertebroplasty | Intervention Type: DEVICE; Name: Percutaneous vertebroplasty; Assigned to Arm(s): Vertebroplasty | Intervention Type: PROCEDURE; Name: Sham vertebroplasty; Assigned to Arm(s): Control Group
C: Arm Label: vertebroplasty; Type: EXPERIMENTAL; Interventions: Procedure: percutaneous vertebroplasty | Arm Label: sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: sham procedure | Intervention Type: PROCEDURE; Name: percutaneous vertebroplasty; Assigned to Arm(s): vertebroplasty | Intervention Type: PROCEDURE; Name: sham procedure; Assigned to Arm(s): sham procedure
D: Arm Label: AVAMAX; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Arm Label: Simulated injection procedure; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): AVAMAX

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Sham Controlled Trial of Vertebroplasty for Painful Acute Osteoporotic Vertebral Fractures
Brief Summary: The standard care in patients with a painful osteoporotic vertebral compression fracture (VCF) is conservative therapy. Percutaneous vertebroplasty (PV), is a new minimally invasive technique for pain treatment in which bone cement is injected in the fractured vertebra. Recent RCTs provide conflicting results: two sham-controlled studies show no benefit of PV while an unmasked but controlled RCT found significantly better pain relief after PV at acceptable costs.


Options:
A: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: percutaneous injection of cement into the vertebral body | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: PROCEDURE; Name: percutaneous injection of cement into the vertebral body; Assigned to Arm(s): vertebroplasty | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical Treatment
B: Arm Label: AVAMAX; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Arm Label: Simulated injection procedure; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): AVAMAX
C: Arm Label: vertebroplasty; Type: EXPERIMENTAL; Interventions: Procedure: percutaneous vertebroplasty | Arm Label: sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: sham procedure | Intervention Type: PROCEDURE; Name: percutaneous vertebroplasty; Assigned to Arm(s): vertebroplasty | Intervention Type: PROCEDURE; Name: sham procedure; Assigned to Arm(s): sham procedure
D: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SMART: A Social and Mobile Weight Control Program for Young Adults
Brief Summary: The Social/Mobile Approach to Reduce Weight (SMART) study is a 24-month randomized control trial designed to evaluate the hypothesis that weight status at 24 months will be significantly better for the SMART intervention recipients than for those who receive the comparison condition.


Options:
A: Arm Label: Social/Mobile Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Social/mobile weight loss promotion intervention. | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Social/mobile weight loss promotion intervention.; Assigned to Arm(s): Social/Mobile Intervention
B: Arm Label: Step 1: Optimal First Line Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Step 1 Treatment: APP, Behavioral: Step 1 Treatment: APP + Coaching | Arm Label: Step 2: Optimal Strategy to Address Nonresponse; Type: EXPERIMENTAL; Interventions: Behavioral: Step 2 Treatment Strategy: Modest Step-up, Behavioral: Step 2 Treatment Strategy: Vigorous Step-up | Intervention Type: BEHAVIORAL; Name: Step 1 Treatment: APP; Assigned to Arm(s): Step 1: Optimal First Line Treatment | Intervention Type: BEHAVIORAL; Name: Step 1 Treatment: APP + Coaching; Assigned to Arm(s): Step 1: Optimal First Line Treatment | Intervention Type: BEHAVIORAL; Name: Step 2 Treatment Strategy: Modest Step-up; Assigned to Arm(s): Step 2: Optimal Strategy to Address Nonresponse | Intervention Type: BEHAVIORAL; Name: Step 2 Treatment Strategy: Vigorous Step-up; Assigned to Arm(s): Step 2: Optimal Strategy to Address Nonresponse
C: Arm Label: Podcasting + mobile media; Type: EXPERIMENTAL; Interventions: Behavioral: Podcasting + mobile media | Arm Label: Podcasting; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Podcasting + mobile media | Intervention Type: BEHAVIORAL; Name: Podcasting + mobile media; Assigned to Arm(s): Podcasting, Podcasting + mobile media
D: Arm Label: Fit and Trim group; Type: EXPERIMENTAL; Interventions: Behavioral: Filipinos Fit and Trim Weight Loss Program | Arm Label: Pedometer only group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Filipinos Fit and Trim Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Filipinos Fit and Trim Weight Loss Program; Assigned to Arm(s): Fit and Trim group, Pedometer only group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Efficacy of Phosphodiesterase-5 Inhibitor Tadalafil in Eisenmenger Syndrome - A Randomised, Placebo Controlled, Double Blind, Crossover Study
Brief Summary: A preliminary observational study by the investigators has shown that tadalafil, a selective phosphodiesterase-5 inhibitor (PDE-5) decreases pulmonary vascular resistance(PVR) in patients of eisenmenger syndrome (ES) resulting in increase in pulmonary blood flow (Qp), systemic oxygen saturation (SaO2), functional class and exercise capacity. The aim of this placebo controlled trial was to assess the effect of the drug on exercise capacity and functional class compared to placebo.


Options:
A: Arm Label: Sildenafil 40mg or 80mg; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil 40mg or 80mg
B: Arm Label: Sildenafil Citrate; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil Citrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil Citrate; Assigned to Arm(s): Sildenafil Citrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sildenafil plus pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil | Arm Label: Placebo plus pulmonary rehabilitation; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil plus pulmonary rehabilitation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo plus pulmonary rehabilitation
D: Arm Label: Tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tadalafil, placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tadalafil, placebo | Intervention Type: DRUG; Name: Tadalafil, placebo; Assigned to Arm(s): Tadalafil, placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigation of the Dynamics of Sitting Postural Control in Infants With Cerebral Palsy
Brief Summary: The overall goal of this research is to understand the mechanisms underlying the development of postural control in sitting using new methodology, in order to provide a scientific basis for evaluation and treatment of posture and movement disorders in infants with cerebral palsy. The development of early posture control remains poorly understood despite considerable therapeutic effort. Infants with cerebral palsy show their first delays in the acquisition of sitting, with subsequent problems developing adequate posture and movement control. Identifying the delay, determining the nature of the problem, and evaluating the effectiveness of treatment quickly, are vital in the early part of an infant's life, since this is the time of greatest plasticity. Tools from nonlinear dynamics, which are increasingly being used to examine other biological rhythms, are used in this study to analyze postural sway from center of pressure data during the development of sitting postural control.


Options:
A: Arm Label: Typically Developing Infants; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy | Arm Label: Perceptual-motor intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy | Intervention Type: OTHER; Name: Physical therapy; Assigned to Arm(s): Home Program, Perceptual-motor intervention
B: Arm Label: Intervention Stationary Cycling; Type: EXPERIMENTAL; Interventions: Other: Stationary Cycling | Intervention Type: OTHER; Name: Stationary Cycling; Assigned to Arm(s): Intervention Stationary Cycling
C: Arm Label: Stabilization Group; Type: EXPERIMENTAL; Interventions: Other: Core Stabilization, Other: Traditional upper extremity rehabilitation | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional upper extremity rehabilitation | Intervention Type: OTHER; Name: Core Stabilization; Assigned to Arm(s): Stabilization Group | Intervention Type: OTHER; Name: Traditional upper extremity rehabilitation; Assigned to Arm(s): Control Group, Stabilization Group
D: Arm Label: Virtual reality video game; Type: ACTIVE_COMPARATOR; Interventions: Other: virtual reality system | Arm Label: Virtual reality system; Type: PLACEBO_COMPARATOR; Interventions: Other: virtual reality system | Intervention Type: OTHER; Name: virtual reality system; Assigned to Arm(s): Virtual reality system, Virtual reality video game

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Case Management for Early Psychosis: is Two Year an Optimal Duration? A Randomized Controlled Study
Brief Summary: A total of 160 subjects, who aged 18-35 and had completed the first 2 years of case management in the EASY programme will be randomized in 1:1 ratio into either (1) receiving an additional year of case management, or (2) terminating case management for the next 12 months. The current study aims to investigate whether an additional year of case management in year 3 will confer additional benefits in outcome, in terms of functioning, symptoms, quality of life and health economics.


Options:
A: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
B: Arm Label: Treatment As Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment As Usual (TAU) | Arm Label: TAU+CBT for pts+Family Intervention+CM; Type: EXPERIMENTAL; Interventions: Behavioral: TAU+CBT for pts+Family Intervention+CM. | Intervention Type: OTHER; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: TAU+CBT for pts+Family Intervention+CM.; Assigned to Arm(s): TAU+CBT for pts+Family Intervention+CM
C: Arm Label: 5 year; Type: EXPERIMENTAL; Interventions: Behavioral: OPUS 5 years | Arm Label: 2 years of OPUS treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 years OPUS treatment | Intervention Type: BEHAVIORAL; Name: 2 years OPUS treatment; Assigned to Arm(s): 2 years of OPUS treatment | Intervention Type: BEHAVIORAL; Name: OPUS 5 years; Assigned to Arm(s): 5 year
D: Arm Label: Case Management (1 year); Type: EXPERIMENTAL; Interventions: Behavioral: Community Case Management | Arm Label: Standard Care (1 year); Type: NO_INTERVENTION; Interventions: Behavioral: Community Case Management | Intervention Type: BEHAVIORAL; Name: Community Case Management; Assigned to Arm(s): Case Management (1 year), Standard Care (1 year)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Case Management for Early Psychosis: is Two Year an Optimal Duration? A Randomized Controlled Study
Brief Summary: A total of 160 subjects, who aged 18-35 and had completed the first 2 years of case management in the EASY programme will be randomized in 1:1 ratio into either (1) receiving an additional year of case management, or (2) terminating case management for the next 12 months. The current study aims to investigate whether an additional year of case management in year 3 will confer additional benefits in outcome, in terms of functioning, symptoms, quality of life and health economics.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Assertive intervention | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Assertive intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): B
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive training | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): 1, 2
C: Arm Label: 5 year; Type: EXPERIMENTAL; Interventions: Behavioral: OPUS 5 years | Arm Label: 2 years of OPUS treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 years OPUS treatment | Intervention Type: BEHAVIORAL; Name: 2 years OPUS treatment; Assigned to Arm(s): 2 years of OPUS treatment | Intervention Type: BEHAVIORAL; Name: OPUS 5 years; Assigned to Arm(s): 5 year
D: Arm Label: Case Management (1 year); Type: EXPERIMENTAL; Interventions: Behavioral: Community Case Management | Arm Label: Standard Care (1 year); Type: NO_INTERVENTION; Interventions: Behavioral: Community Case Management | Intervention Type: BEHAVIORAL; Name: Community Case Management; Assigned to Arm(s): Case Management (1 year), Standard Care (1 year)

Answer: D